PFAS: Thinking Beyond the Dose

Traditional toxicology has long been guided by the principle that “the dose makes the poison.” The greater the exposure, the greater the potential health risk. Developmental toxicology introduces another dimension to that equation: When did exposure occur?

During fetal development and early childhood, organs, immune systems, endocrine pathways, and neurological functions undergo rapid growth and complex biological programming. Disruptions during these critical windows may have consequences that differ substantially from identical exposures experienced during adulthood. This concept is already well established for substances such as lead, mercury, and certain endocrine-disrupting chemicals.

Regulatory agencies routinely develop separate exposure recommendations for pregnant women and children because these populations exhibit different sensitivities. PFAS research increasingly appears to be following a similar trajectory.

Recent studies have examined associations between prenatal PFAS exposure and immune function, vaccine response, birth outcomes, metabolic health, and neurodevelopment. Although many questions remain regarding causality, dose-response relationships, and the biological mechanisms involved, the accumulating evidence is shifting scientific attention toward developmental health endpoints.

Dose, Timing, and Mixture

A Mount Sinai study published in the July 2026 issue of Clinical Gastroenterology and Hepatology contributes to that broader trend by suggesting that gastrointestinal health may also deserve greater attention within PFAS risk assessment. Perhaps equally important is the study’s focus on PFAS mixtures rather than individual compounds.

People are rarely exposed to a single PFAS in isolation. Drinking water, food, consumer products, and occupational settings often involve exposure to multiple PFAS simultaneously. Understanding how these mixtures interact remains one of the most significant scientific challenges facing toxicologists.

“Studying them individually is easier to do and easier to understand, but how relevant is that when we’re really exposed to them simultaneously as a mixture? That’s what we wanted to address in this paper. We wanted to consider the mixture because of its practical relevance,” explained study author Dr. Vishal Midya, an assistant professor of environmental medicine and public health at the Icahn School of Medicine at Mount Sinai, in an interview with 3E.

The consistency of the study’s findings across multiple biological samples and three independent birth cohorts strengthens the evidence that early-life PFAS exposure may have lasting effects on intestinal health, he said.

Rethinking Risk Assessment

The convergence of these scientific developments raises broader questions about how chemical risk assessments are conducted. Historically, many regulatory frameworks have relied heavily on adult exposure scenarios, lifetime-average exposure assumptions, and toxicity data generated for individual chemicals. These approaches have formed the foundation of chemical regulation for decades and remain scientifically robust for many applications.

Emerging PFAS research, however, is challenging some of those traditional assumptions.

Scientists increasingly argue that future risk assessments may need to place greater emphasis on prenatal exposure, cumulative exposure across multiple pathways, susceptible populations, and mixture effects. Rather than asking whether an average adult is adequately protected, regulators may increasingly ask whether existing limits are sufficiently protective for a developing fetus or young child.

This shift mirrors broader trends across environmental health science. Risk assessment has gradually evolved from evaluating individual hazards to understanding how genetics, nutrition, socioeconomic factors, chemical mixtures, and life-stage susceptibility influence overall health outcomes.

Monitoring is evolving in parallel. Advances in biomonitoring, high-resolution analytical chemistry, exposomics, and computational toxicology are providing researchers with increasingly sophisticated tools for evaluating real-world exposures. As these capabilities expand, regulatory agencies may have opportunities to refine both exposure assessment and health-based standards.

What This Means for Industry

For manufacturers, downstream users, and compliance professionals, these developments signal more than another chapter in the ongoing PFAS regulatory story. Future expectations may extend beyond demonstrating compliance with environmental limits. Companies could increasingly be expected to understand how products contribute to lifetime exposure, evaluate potential impacts on vulnerable populations, and generate data supporting the safety of replacement chemistries.

Chemical stewardship programs may also shift. Product developers may face greater scrutiny regarding developmental toxicity, mixture effects, and long-term exposure potential during product design rather than after commercialization.

More broadly, organizations throughout the chemical value chain may find that exposure characterization becomes as important as hazard identification. Understanding who is exposed, when exposures occur, and how those exposures are measured could become central components of future regulatory compliance.

One thing is certain: PFAS policy is expanding beyond contamination cleanup toward a more comprehensive understanding of exposure across the human lifespan.

Evolution of PFAS Risk Assessment

The next generation of PFAS regulation may be defined less by the discovery of new contaminants than by advances in exposure science. As regulators continue lowering permissible concentrations, analytical capabilities must keep pace to ensure that monitoring data are reliable, reproducible, and meaningful. Setting protective standards is essential, but those standards are only as effective as the systems used to measure them.

At the same time, emerging health research is broadening the conversation beyond adult exposure scenarios. Studies examining prenatal and childhood exposures suggest that vulnerability is not distributed equally across the population. Instead, risk may depend not only on how much PFAS a person encounters but also on when exposure occurs and whether it coincides with critical stages of development.

For regulators, these parallel developments raise important questions about the future of chemical risk assessment. Will monitoring programs need to become more sensitive? Should health-based standards place greater emphasis on developmental endpoints? And how should risk assessments account for real-world exposure to complex PFAS mixtures rather than individual compounds?

The answers will likely shape PFAS policy for years to come. As analytical chemistry, toxicology, and epidemiology continue to advance, the focus of regulation appears to be shifting from simply detecting PFAS to understanding which exposures matter most - and ensuring that the people most vulnerable to their effects are adequately protected.

This is Part 3 of a four-part series. Read the other articles in the series: The Next Frontier in PFAS Regulation: Measuring What Matters (Part 1), PFAS: Detection Is Becoming the New Bottleneck (Part 2), and Looking Beyond Individual Chemicals: Why PFAS Risk Assessment Is Evolving (Part 4).